Switch to:
More From Other Websites
Will Sarepta reverse after steep drop? Feb 05 2016
It’s Time to Buy This Biotech Gem Feb 04 2016
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 02 2016
Top 10 BioFlash stories in January: Duchenne news dominates once again Feb 01 2016
3 Key FDA Decisions Expected in February Jan 31 2016
Structural Volatility Won't End For Several Years, Derivatives Strategist Says Jan 27 2016
Bragar Eagel & Squire, P.C. Is Investigating the Officers and Directors of Sarepta Therapeutics,... Jan 26 2016
Duchenne drug by Cambridge's Catabasis looks safe in early trial Jan 25 2016
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Sarepta... Jan 24 2016
Biotech Stock Mailbag: Snow Stops Sarepta's FDA Show, so What's Next? Jan 24 2016
Lifshitz & Miller Law Firm Announces Investigation of GoPro Inc., Iconix Brand Group, Inland Real... Jan 22 2016
Forbes: There Is 'A Bit' Of Hope For Sarepta Therapeutics Jan 22 2016
Snowstorm Dashes Hopes for Sarepta Drug's Dystrophy Patients Jan 22 2016
Is There Hope For Sarepta Therapeutics? Yes, A Bit Jan 22 2016
The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug Jan 21 2016
FDA Snow Delay Adds To Woes For Sarepta's Muscular Dystrophy Med Jan 21 2016
Technical Scrutiny on Biotechnology Stocks -- Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and... Jan 21 2016
INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Sarepta... Jan 20 2016
Snow delays FDA hearing; Duchenne drug advocates vow to redouble efforts Jan 20 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK